An interventional study of Yiqi huoxue and Yiqi group in Cerebral Infarction, sponsored by Dongfang Hospital Beijing University of Chinese Medicine. Status unknown at 3 sites in China. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-02-12.
Sponsored by Dongfang Hospital Beijing University of Chinese Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Cerebral Infarction with a site in China — 16 open to participants now, 18 under way, 3 of them phase 3. Cerebral Infarction · China.
Among the 58 studies in Cerebral Infarction with a site in China, this one is the 13th largest by planned enrollment of the 37 interventional ones that give a count, is one of 3 that started in 2016, is one of 13 with no phase, and was the 16th registered.
219 studies on the registry are indexed under Cerebral Infarction; 46 are open to participants now.
Browse Cerebral Infarction studies →16 of the 58 studies in Cerebral Infarction with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–80
Weifang Medical University · Sites in China
Ages 18+
Nanchang University Affiliated Rehabilitation Hospital · Sites in China
Ages 18–80
Zhujiang Hospital · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 27 Cerebral Infarction studies recruiting now, 19 (70%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 35 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 6 · Phase 4 8
First in 2000; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 120 across 139 interventional studies indexed under Cerebral Infarction.
Median enrollment 210 across the 37 interventional studies, 1,000 across the 21 observational. Of the 18 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 58 have an industry lead sponsor. The 10 most frequent:
Dongfang Hospital Beijing University of Chinese Medicine is the lead sponsor of 10 studies on the registry; none are open to participants now.
Dongfang Hospital Beijing University of Chinese Medicine has 1 study filed under Cerebral Infarction — fewer than ten, so there is no comparison to draw.
3 of the studies in Cerebral Infarction with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07115459Xiangya Hospital of Central South UniversityDevelopment and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring | 2026-12-31 |
| NCT07081568Nanchang University Affiliated Rehabilitation HospitalResearch on Binaural Synchronous Vagus Nerve Regulation of Sensorimotor Disorders After Cerebral Infarction | 2027-06-30 |
| NCT07563673Beijing Chao Yang HospitalEarly Low-dose ASpirin Use After Intravenous Thrombolysis for Acute Ischemic Cerebral Infarction(ELASTIC) | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 58 studies in Cerebral Infarction with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This clinical research is based on the fundamentals of using Chinese medicine, which will improve Qi and promote blood circulation, to treat patients in the recuperating stages of cerebral infarction with deficiency in Qi and blood stasis syndrome. By assimilating Chinese medical theory, this research aims to study the biological basics of the stroke and the cause for the deficiency in Qi and blood stasis syndrome; explore the therapeutic mechanism of the treatment methods; as well as ascertaining the relationship between Qi, blood and blood vessels.
Cerebral infarction, or ischemic stroke, is a common yet challenged illness with four telltale signs (high occurrence rate, high incapacitate rate, high mortality rate, and high recurrence rate), posing not only a threat to a man's health and life, but also imposing a burden to the society and his loved ones. As such, seeking a cure has always been the hot topic in this field of research. With regard to the illness' high incapacitate and recurrence rates, it has become apparent that the treatment methods used in the recuperating stages of stroke are very significant to the patient, allowing him the chance to regain his health and increase his quality of life. In Chinese medical terms, the pathogenesis key of stroke is a deficiency in the vitals of the body coupled with superficiality extremities. As such, in the recuperating stage of the stroke, a lack of Qi accompanied with blood stasis syndrome is often observed. Hence, improving Qi and promoting blood circulation is essential during treatment. Research further supports that this treatment method is highly effective in treating cerebral infarction, but the mechanism involved is still incomprehensible, largely due to the fact that the pathology of cerebral infraction is highly complicated, and that Chinese medicine is multi-leveled, multi-channeled, with multi-targets. To further study the relationship of Qi and blood in cerebral infraction, patients in the recuperating stages with deficiency in Qi and blood stasis underwent observation in a double blind clinical research. The patients were sorted in random into groups: improving Qi group, promoting blood circulation group, improving Qi and promoting blood circulation group, and the control group. Each group of patients was given the standard Western medicine treatment, coupled with Chinese medicine treatments with respect to their sorted groupings. The treatment lasts for 12 weeks and 360 clinical cases were studied. Testing methods used include enzyme linked immunosorbent assay, Western Blot, FQ RT-PCR, LC-MS, and radiology. Through the relations between Neurotransmitter - endocrine hormone - immune cytokine network, blood rheology, vascular structure and endothelial function, interactions involving vasoactive substances with vascular endothelium and blood cells, it is hoped that the biological basis of cerebral infraction's deficiency in Qi and blood stasis syndrome can be deciphered. This will aid in the understanding of the whole process of causing the syndrome, deciphering the therapeutic mechanism involved during treatment, as well as determining the relationship between Qi, blood and blood vessels.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Buyang Huanwu decoction , which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Drug: Yiqi huoxue
Astragalus 60g. Oral administration, twice one day, for 12weeks.
Drug: Yiqi group
Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Drug: Huoxue group
dextrin, Oral administration, twice one day, for 12weeks.
Drug: placebo
Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Also known as: tonifying Qi and activating blood
Astragalus 60g.Oral administration, twice one day, for 12weeks.
Also known as: tonifying qi, benefiting qi
Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
Also known as: activating blood
Dextrin,oral administration, twice one day, for 12weeks.
Also known as: a soothing restorative agency
National Institute of Health Stroke Scale
NIHSS
Time frame: 12 weeks
Modified Rankin scale
0-5scales
Time frame: 12 weeks
Barthel index
0-100scales
Time frame: 12 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Mar 2016, a primary completion of Dec 2019 and a completion of Dec 2019. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dongfang Hospital Beijing University of Chinese Medicine